Listar Unidade de investigación en Enfermidades Infecciosas: Hepatite e SIDA por autor "Martín-Herranz, Isabel"
Mostrando ítems 1-2 de 2
-
Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients: results in real clinical practice
Margusino-Framiñán, Luis; Cid-Silva, Purificación; Mena, Álvaro; Rodríguez-Osorio, Iria; Pernas, Berta; Delgado, Manuel; Pértega-Díaz, Sonia; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles (Sociedad Española de Quimioterapia, 2019)[Abstract] OBJECTIVE: Direct-acting antivirals have shown high efficacy in all hepatitis C virus (HCV) genotypes, but genotype 3 (G3) treatments continue to be a challenge, mainly in cirrhotic patients. The aim of this ... -
Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV‐infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine
Cid-Silva, Purificación; Fernández-Bargiela, Noelia; Margusino-Framiñán, Luis; Balboa-Barreiro, Vanesa; Mena, Álvaro; López-Calvo, Soledad; Vázquez-Rodríguez, Pilar; Martín-Herranz, Isabel; Míguez-Rey, Martín; Poveda, Eva; Castro-Iglesias, Ángeles (Wiley, 2018-11-02)[Abstract] Two elvitegravir/cobicistat‐based therapies combined with emtricitabine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF) or emtricitabine/tenofovir alafenamide fumarate (EVG/c/FTC/TAF) are currently available for ...